Mereo BioPharma updates progress on Phase 3 studies for setrusumab and alvelestat

From GlobeNewswire: 2025-01-12 11:05:16

Mereo BioPharma continues Phase 3 study of setrusumab in osteogenesis imperfecta, with planned second interim analysis in mid-2025. Alvelestat for Alpha-1 Antitrypsin Deficiency-associated Lung Disease receives positive EMA opinion for European Orphan Designation Application, awaiting final decision in Q1 2025. Setrusumab Phase 3 Orbit Study progresses towards second interim analysis in mid-2025, with potential final analysis in Q4 2025. Alvelestat receives positive opinion from EMA’s COMP for Orphan Designation, final decision expected in Q1 2025. EU Orphan Designation provides benefits for therapeutics targeting rare diseases. Mereo BioPharma focuses on rare disease product candidates setrusumab and alvelestat.



Read more at GlobeNewswire: Mereo BioPharma Provides Update on Lead Clinical Programs